Biomerieux, Inc.

Biomerieux Sa

Hospices Civils De Lyon

Centre Hospitalier Universitaire De Nantes

Sylvie Pons

Jean-Philippe Charrier

Corinne Beaulieu

Guillaume Monneret

Genevieve Choquet-Kastylevsky

Yasemin Ataman-Onal

Yannick Charretier

Tanguy Fortin

Fabienne Venet

Dominique Rolland

Christine Franceschi

Alexandre Pachot

Karim Asehnoune

Victoria Girard

Marilyne Dupin

Geneviève Choquet-Kastylevsky

Yasemin Ataman-Önal

Antoine Roquilly

Sonia Chatellier

Bernard Allaouchiche

Philippe Dufour

Aurélie Gouel-Cheron

Audrey Larue-Triolet

A method for predicting the risk of developing a disseminated infection in a patient admitted to intensive care having no clinical symptoms of such infection includes: determining a first dose of gelsolin G1 in a biological sample from the patient originating from a first sample taken at time T1, carried out between the day of intensive care admission and 48 hours afterward; determining a second dose of gelsolin G2 in a biological sample from the patient originating from a second sample taken at time T2, carried out two to three days after the first sampling; calculating the variation between the dose of gelsolin G2 and the dose of gelsolin G1, giving a &#x394; value; and comparing the &#x394; value to a threshold value S determined beforehand from two patient populations admitted to intensive care, one not having developed a disseminated infection and the other having developed such an infection.

Prediction of the risk of developing a disseminated infection for patients admitted to an intensive care unit

A method for characterizing at least one microorganism from a sample includes identifying the at least one microorganism and determining the properties of typing, potential resistance to at least one antimicrobial, and virulence factor. The properties of typing, resistance to at least one antimicrobial, and virulence factor for the at least one microorganism are determined by implementing mass spectrometry using proteins, peptides and/or metabolites as markers of the properties of typing, resistance to at least one antimicrobial, and virulence factor.

Method for characterizing at least one microorganism by means of mass spectrometry

A method for the in vitro diagnosis of colorectal cancer by determining the presence of Liver Fatty Acid-Binding Protein, ACE and CA19-9 tumor markers in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.

Method for the assay of liver fatty acid binding protein, ACE and CA 19-9 for the in vitro diagnosis of colorectal cancer

Growing community of inventors

Saint Genis les Ollieres, France

Sylvie Pons